AU2002345024B2 - Tablet comprising cetirizine and pseudoephedrine - Google Patents

Tablet comprising cetirizine and pseudoephedrine Download PDF

Info

Publication number
AU2002345024B2
AU2002345024B2 AU2002345024A AU2002345024A AU2002345024B2 AU 2002345024 B2 AU2002345024 B2 AU 2002345024B2 AU 2002345024 A AU2002345024 A AU 2002345024A AU 2002345024 A AU2002345024 A AU 2002345024A AU 2002345024 B2 AU2002345024 B2 AU 2002345024B2
Authority
AU
Australia
Prior art keywords
cetirizine
pseudoephedrine
tablet
tablet according
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002345024A
Other languages
English (en)
Other versions
AU2002345024A1 (en
Inventor
Monique Berwaer
Michel Deleers
Domenico Fanara
Anthony Guichaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Farchim SA
Original Assignee
UCB Farchim SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Farchim SA filed Critical UCB Farchim SA
Publication of AU2002345024A1 publication Critical patent/AU2002345024A1/en
Assigned to UCB FARCHIM SA reassignment UCB FARCHIM SA Amend patent request/document other than specification (104) Assignors: UCB, FARCHIM, S.A.
Application granted granted Critical
Publication of AU2002345024B2 publication Critical patent/AU2002345024B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2002345024A 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine Ceased AU2002345024B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30125001P 2001-06-28 2001-06-28
US60/301,250 2001-06-28
EP01115807 2001-06-28
EP01115807.8 2001-06-28
PCT/EP2002/006342 WO2003002098A1 (en) 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine

Publications (2)

Publication Number Publication Date
AU2002345024A1 AU2002345024A1 (en) 2003-05-15
AU2002345024B2 true AU2002345024B2 (en) 2006-09-07

Family

ID=56290291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002345024A Ceased AU2002345024B2 (en) 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine

Country Status (22)

Country Link
EP (1) EP1404304B1 (enExample)
JP (1) JP4041460B2 (enExample)
KR (1) KR100926410B1 (enExample)
CN (1) CN100490809C (enExample)
AT (1) ATE432068T1 (enExample)
AU (1) AU2002345024B2 (enExample)
BR (1) BR0210650A (enExample)
CA (1) CA2451519C (enExample)
CZ (1) CZ20033454A3 (enExample)
DK (1) DK1404304T3 (enExample)
EE (1) EE05357B1 (enExample)
ES (1) ES2324769T3 (enExample)
HU (1) HU229803B1 (enExample)
MX (1) MXPA03010430A (enExample)
NZ (1) NZ530289A (enExample)
PL (1) PL206069B1 (enExample)
PT (1) PT1404304E (enExample)
RO (1) RO122476B1 (enExample)
RU (1) RU2286784C2 (enExample)
SI (1) SI1404304T1 (enExample)
SK (1) SK287645B6 (enExample)
WO (1) WO2003002098A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090029314A (ko) * 2001-06-28 2009-03-20 유씨비 파쉼 소시에떼아노님 세티리진 및 슈도에페드린을 포함하는 정제
KR100698400B1 (ko) 2004-04-14 2007-03-23 이은주 탈모증 및 전립선비대증 치료를 위한 약제학적 조성물
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
ES2705244T3 (es) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
KR101372324B1 (ko) * 2012-02-09 2014-03-13 동국대학교 경주캠퍼스 산학협력단 알러지성 비염 치료를 위한 한방 치료제 및 슈도에페드린을 함유한 복합서방형의 약제학적 조성물
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2016140630A1 (en) 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
US20210236430A1 (en) * 2020-02-03 2021-08-05 Johnson & Johnson Consumer Inc. Single layer chewable tablet comprising cetirizine
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
WO1998041194A1 (fr) * 1997-03-14 1998-09-24 Ucb, S.A. Compositions pharmaceutiques pour la liberation controlee de substances actives
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
WO1998041194A1 (fr) * 1997-03-14 1998-09-24 Ucb, S.A. Compositions pharmaceutiques pour la liberation controlee de substances actives
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Also Published As

Publication number Publication date
EP1404304A1 (en) 2004-04-07
HUP0400386A2 (hu) 2004-08-30
EE05357B1 (et) 2010-12-15
CA2451519A1 (en) 2003-01-09
ES2324769T3 (es) 2009-08-14
RU2286784C2 (ru) 2006-11-10
PL366800A1 (en) 2005-02-07
CA2451519C (en) 2007-11-06
RU2004101231A (ru) 2005-04-20
ATE432068T1 (de) 2009-06-15
BR0210650A (pt) 2004-10-05
KR100926410B1 (ko) 2009-11-12
MXPA03010430A (es) 2004-12-06
HU229803B1 (en) 2014-07-28
JP4041460B2 (ja) 2008-01-30
PL206069B1 (pl) 2010-06-30
JP2004536829A (ja) 2004-12-09
RO122476B1 (ro) 2009-07-30
CN100490809C (zh) 2009-05-27
SI1404304T1 (sl) 2009-10-31
HUP0400386A3 (en) 2006-02-28
CZ20033454A3 (cs) 2004-08-18
SK287645B6 (sk) 2011-05-06
WO2003002098A1 (en) 2003-01-09
PT1404304E (pt) 2009-06-26
NZ530289A (en) 2004-11-26
KR20040007756A (ko) 2004-01-24
EP1404304B1 (en) 2009-05-27
CN1520285A (zh) 2004-08-11
SK15502003A3 (sk) 2004-05-04
DK1404304T3 (da) 2009-07-13
EE200400005A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
CA2451519C (en) Tablet comprising cetirizine and pseudoephedrine
JP2007176958A (ja) セチリジン及びプソイドエフェドリンを含む錠剤
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine
US20050171119A1 (en) Pharmaceutical formulations with modified release
AU2002253425B2 (en) Novel pharmaceutical compositions for antihistaminic-decongenstant combination and method of making such compositions
HK1064596B (en) Tablet comprising cetirizine and pseudoephedrine
WO2007143290A2 (en) Delayed-release compositions of extended release forms of venlafaxine
TWI243061B (en) Tablet comprising cetirizine and pseudoephedrine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT/PATENTEE FROM UCB, FARCHIM, S.A. TO UCB FARCHIM SA.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired